15 June 2009 - Gentronix and Apredica have announced a strategic alliance to provide drug-discovery support services in the area of predictive toxicology.
The objective of the alliance is to reduce the failure rate of drugs in late development, particularly due to toxicity, thereby improving the efficiency of drug discovery and increasing assurance that new drugs are safe.
In addition to the joint service offering, UK-based Gentronix and US-based Apredica have also agreed to become mutual agents.
The alliance offers a new suite of predictive in vitro toxicology services to help improve the speed and efficiency of drug development.
